{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:40:05Z","timestamp":1777642805482,"version":"3.51.4"},"reference-count":25,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"30","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2008,10,20]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity in a variety of hematologic malignancies, including non-Hodgkin's lymphoma (NHL). We report the results of a phase II, single-arm, multicenter trial evaluating the safety and efficacy of lenalidomide oral monotherapy in patients with relapsed or refractory aggressive NHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>Patients were treated with oral lenalidomide 25 mg once daily on days 1 to 21, every 28 days, for 52 weeks, until disease progression or intolerance. The primary end point was response; secondary end points included duration of response, progression-free survival (PFS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-nine patients with a median age of 65 years received lenalidomide in this study. The most common histology was diffuse large B-cell lymphoma (53%), and patients had received a median of four prior treatment regimens for NHL. An objective response rate of 35% was observed in 49 treated patients, including a 12% rate of complete response\/unconfirmed complete response. Responses were observed in each aggressive histologic subtype tested (diffuse large B-cell, follicular center grade 3, mantle cell, and transformed lymphomas). Of patients with stable disease or partial response at first assessment, 25% improved with continued treatment. Estimated median duration of response was 6.2 months, and median PFS was 4.0 months. The most common grade 4 adverse events were neutropenia (8.2%) and thrombocytopenia (8.2%); the most common grade 3 adverse events were neutropenia (24.5%), leukopenia (14.3%), and thrombocytopenia (12.2%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.2007.15.3429","type":"journal-article","created":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T21:09:10Z","timestamp":1215464950000},"page":"4952-4957","source":"Crossref","is-referenced-by-count":322,"title":["Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma"],"prefix":"10.1200","volume":"26","author":[{"given":"Peter H.","family":"Wiernik","sequence":"first","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Tuscano","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glen","family":"Justice","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig E.","family":"Cole","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Lam","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"McBride","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenton","family":"Wride","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Pietronigro","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Takeshita","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Ervin-Haynes","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome B.","family":"Zeldis","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas M.","family":"Habermann","sequence":"additional","affiliation":[{"name":"From Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY; Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL; University of California, Davis Cancer Center, Sacramento; Pacific Coast Hematology\/Oncology Medical Group, Fountain Valley, CA; University of Nebraska, Nebraska Medical Center, Omaha, NE; Gundersen Clinic, La Crosse, WI; BC Community Oncology Trialists, Burnaby, British Columbia, Canada; Instat Services, Chatham; Celgene Corporation, Summit, NJ; and Mayo..."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011795"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.131"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Morrison VA, Weller EA, Habermann TM, et al: Maintenance rituximab (MR) compared to observation (OBS) after R-CHOP or CHOP in older patients (pts) with diffuse large B-cell lymphoma (DLBCL): An Intergroup E4494\/C9793 update. J Clin Oncol 25:443s,2007,  (suppl; abstr 8011)","DOI":"10.1200\/jco.2007.25.18_suppl.8011"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.55.017"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162401"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1323"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4184"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.01.010"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2317"},{"key":"R12","unstructured":"Galustian C, Klaschka, DC, Meyer B, et al: Lenalidomide (Revlimid, CC-5013) and Actimid (CC-4047) inhibit the function and expansion of T regulatory (Treg) cells in vitro: Implications for anti-tumor activity in vivo. Proc Am Assoc Cancer Res 47:754a,2006,  (abstr 4882)"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402745"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0996"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.108"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3786"},{"key":"R18","unstructured":"Coiffier B, Haioun N, Ketterer N, et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 92:1927,1998-1932,"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0577"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Bartlett JB, Wu L, Adams M, et al: Lenalidomide and pomalidomide strongly enhance tumor cell killing in vitro during antibody-dependent cellular cytotoxicity (ADCC) mediated by trastuzumab, cetuximab and rituximab. J Clin Oncol 25:123s,2007,  (suppl; abstr 3023)","DOI":"10.1200\/jco.2007.25.18_suppl.3023"},{"key":"R21","unstructured":"Wu L, Adams M, Schafer P, et al: Lenalidomide strongly enhances natural killer cell and monocyte mediated antibody-dependent cellular cytotoxicity of rituximab treated CD20+ve cancer cells in vitro. Haematologica 92:113,2007,  (suppl 1; abstr 0314)"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Wang M, Fayad L, Hagemeister F, et al: A phase I\/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed\/refractory mantle cell lymphoma (MCL) with early evidence of efficacy. J Clin Oncol 25:448s,2007,  (suppl; abstr 8030)","DOI":"10.1200\/jco.2007.25.18_suppl.8030"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-077099"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767030-00002"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1080\/07357900701579570"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2007.15.3429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:25:10Z","timestamp":1653510310000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2007.15.3429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10,20]]},"references-count":25,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2008,10,20]]}},"alternative-id":["10.1200\/JCO.2007.15.3429"],"URL":"https:\/\/doi.org\/10.1200\/jco.2007.15.3429","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1126790.584169","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.1126790.583877","asserted-by":"object"}]},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,20]]}}}